Issuing a draft list of revised risk-based classification of cardiovascular and neurological devices, the Central Drugs ...

and transjugular intrahepatic portosystemic stent shunt (TIPSS) placement. The US holds approximately 60% of the thrombocytopenia market share, surpassing the combined market size of the EU4 ...

The trial is designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate device in ...

Stents were patent without evidence of restenosis ... with frequent recurrences over time. Shunt revisions are necessary in 38–63% of patients. Furthermore, although rare, serious complications ...

The gastrorenal shunts can vary in size; however ... Seike Y, Matsuda H, Shimizu H, et al. Japanese Committee for Stent-graft Management (JACSM). Nationwide analysis of persistent type II endoleak and ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having ...

CHICAGO — Patients with severe triple-vessel heart disease who underwent a less-invasive stent procedure fared just as well as those who underwent open-heart bypass surgery after 5 years ...

Currently, all drug-eluting stents (DES), used to treat blocked heart arteries, are priced at Rs 35,000. (Image Credits: Pixabay) Gujarat government has introduced different prices for stents to ...